Evaluation of antiphospholipid antibodies (aPL) and correlation with heart valve abnormalities among patients with systemic lupus erythematosus (SLE). Nested case-control study was conducted with 70 patients with SLE selected from a longitudinal database based on levels of aPL and presence or absence of valve disease by echocardiogram. Valvular abnormalities observed were regurgitation (52), other (14), artificial valves (4), stenosis (2), thickening (2) and no Libman-Sacks endocarditis (0). The mitral valve was the most commonly affected (30 abnormalities), followed by the tricuspid (20 abnormalities). Multivariate logistic regression for those with and without an aPL value ≥20 units/mL, adjusted for disease duration and age, showed significant differences for any valve abnormality (odds ratio [OR] ¼ 3.1; 95% CI: 1.0-8.9; P ¼ 0.041) and individually for the tricuspid valve (OR ¼ 3.3; 95% CI: 1.0-11.1; P ¼ 0.052) but not for the mitral valve (OR ¼ 2.1; 95% CI: 0.68-6.45; P ¼ 0.195). Levels of aPL ≥20 units/mL showed no association with aortic (P ¼ 0.253), pulmonic (P ¼ 1.000), tricuspid (P ¼ 0.127), or mitral (P ¼ 0.249) valve abnormalities. Levels of aPL correlate with certain valvular abnormalities among patients with SLE.
INTRODUCTION
E levated levels of antiphospholipid antibodies (aPL) can be seen among patients with systemic lupus erythematosus (SLE) and are often associated with clinical hypercoagulability. Antiphospholipid syndrome (APS), whether primary or secondary in the setting of SLE, often presents as arterial or venous thrombosis and pregnancy loss. Thrombocytopenia is present in approximately 20% of APS cases, ranging from 50-140,000 platelets/mm 3 . 1 The formation of beta 2 glycoprotein I (B 2 GPI)/aPL immune complexes can deposit and damage valvular surfaces, predisposing to hemodynamic dysfunction and thromboembolic events. Thus, it can be speculated that heart valve disease (HVD) may be a predictive factor for APS-related complications.
The aPL antibodies of interest are the lupus anticoagulant (LA), anticardiolipin (aCL) and anti-beta 2 glycoprotein I antibodies. These are found elevated in approximately 1-6% of the general population. 2 These antibodies are directed against negatively charged phospholipids and plasma proteins, particularly the B 2 GPI. This protein has been shown to form complexes with anionic phospholipids resulting in inhibitory functions in coagulation pathways.
Autoimmune-mediated and inflammatory cardiovascular damage is one of the common causes of mortality in SLE. 3 It is currently well recognized that patients can have clinically significant cardiac valve disease, typically aortic insufficiency, leading to prosthetic valve replacement. The classic cardiac lesion of SLE is Libman-Sacks Endocarditis, which manifests as an atypical endocarditis with 1-4 mm verrucous vegetations present on either side of the mitral and aortic valves. Studies by Ziporen et al 4 and Eiken et al 5 found aPL immune complexes, complement fragments, fibrin and platelets in valvular vegetations among patients with SLE in Libman-Sacks endocarditis valve specimen studies. The prevailing theory behind SLE-related valvular disease is that aPL contribute to damage via inflammatory and thrombotic-mediated pathways. Specifically, aPL immune complexes interact with different cells inducing a proinflammatory or coagulatory environment.
Previous studies examining the role of aPL in SLE HVD were limited by small sample sizes and by inconsistent cutoffs used for defining elevated aPL levels. Our study sets out to determine the association of heart valve abnormalities with aPL levels among well characterized patients with SLE followed in a longitudinal registry to address these questions.
PATIENTS AND METHODS

Study Design
This research was carried out with the approval of the Institutional Review Board at the Medical University of South Carolina (MUSC). This study was conducted by reviewing data collected within the longitudinal SLE Database at MUSC. This was a retrospective observational nested case-control study investigating the presence of cardiac valve abnormalities by echocardiogram in relation to aPL levels. All patients with SLE who had an echocardiogram and aPL levels from the database were included in the study.
Study Population
Eligible patients were as follows: (1) age 10 years and above, (2) classified as having "definite" SLE, meeting at least 4 of the 11 revised 1997 American College of Rheumatology (ACR) classification criteria, 6,7 (3) able and willing to give informed consent, (4) available echocardiogram report and (5) available aPL levels. Approximately 75% of patients with SLE within the database were African American, with most of them being Gullah African American. This is a unique population from the Sea Islands of South Carolina and Georgia with lower European admixture and greater genetic homogeneity compared to other African American populations, as previously described. 8 
Variables
Study subjects were split into aPL negative (levels o20 units/mL), aPL low positive (levels between 20 and 40 units/mL) and aPL high positive (levels ≥40) groups based on the following antibodies: aCL immunoglobulin M (IgM), immunoglobulin G (IgG), as well as anti-B 2 GPI IgM, IgG. 9 Echocardiogram reports were assessed for valvular thickening, Libman-Sacks endocarditis, stenosis, regurgitation and artificial valve placement. Nonhemodynamic valvular abnormalities such as calcifications and sclerosis were categorized together as "Other Findings." Childhood-onset SLE was defined as being diagnosed with SLE o18 years of age.
Statistical Analyses
An a priori sample size calculation was conducted, using a power of 0.8 and Type I error probability of 0.05. Based on prior literature, we calculated a sample size of 70 subjects required for our study, assuming that the true probability of any valve disease among aPL-positive patients to be 0.3.
Before conducting the formal hypothesis tests, descriptive statistics were generated and differences at baseline were tested. To assess differences in proportions, Pearson's chi-squared tests or Fisher's exact tests were performed, as appropriate. Single-variable regression models were performed to examine abnormalities in any valve as well as individual valves in relation to race, sex, age of SLE onset, SLE duration and age at visit and thrombocytopenia. Multivariate logistic regression models, adjusted for disease duration and age, were performed to assess associations between aPL levels and valve abnormalities. Significance was set at an alpha of 0.05. All statistical analyses were performed using Stata v14.
RESULTS
Data were collected from patients with SLE with known diagnosis dates; demographics and clinical measures are presented in Table 1 . The study population consisted primarily of African American (69%) females (93%). Mean age at the time of the study visit was 34.0 years (standard deviation [sd] ¼ 16.7). The mean age at SLE diagnosis was 27.2 years (sd ¼ 15.6) with average disease duration of 6.8 years (sd ¼ 7.3). No significant difference was seen between the negative and positive aPL groups in regard to age, sex, disease duration, age at diagnosis and ethnicity as seen in Table 1 .
The most common echocardiogram findings among the patients with SLE in our study were valvular abnormalities (61% of patients). The second was pericardial effusion (39% of patients), and third was diastolic dysfunction (29% of patients). Only 1 patient had an ejection fraction less than 40%. There was no significant difference in pericardial effusion prevalence in relationship to aPl status (P ¼ 0.337). There was also no significant difference found in diastolic dysfunction prevalence in relationship to aPl status (P ¼ 0.662).
Among the 70 patients, the mitral valve had the highest number of abnormalities (30), followed by the tricuspid (20) , aortic (15) and pulmonic valves (9) . Eight patients had more than one valve abnormality present. The most common valve abnormality overall was regurgitation, with 52 cases. Valve regurgitation was evident on echocardiogram in 19 tricuspid, 18 mitral, 8 pulmonic and 7 aortic valves. There were 14 nonhemodynamically significant "other findings" (6 mitral and 6 aortic valves) and 3 patients with mechanical or artificial valve replacements. Two occurrences of stenosis and thickening each were also found. Libman-Sacks endocarditis was not found in this cohort, including a chart review of the 3 patients with valve replacements. Details are shown in Table 1 .
Pearson chi-squared analysis and Fisher's Exact test were conducted to compare valve abnormalities between aPL negative or positive groups of patients. No significant association was found between aPL group and valve abnormalities for the tricuspid (P ¼ 0.127), mitral (P ¼ 0.249), aortic (P ¼ 0.253), or pulmonic valves (P ¼ 1.000). Echocardiograms were not able to visualize a certain valve in a few cases, explaining why some valve groups had less than 70 patients (Table 1) .
Using single-variable regression models (Table 2 ), significant associations were seen between abnormalities in any valve and aPL levels ≥20 units/mL (odds ratio [OR] ¼ 3.3; 95% CI: 1.1-7.8; P ¼ 0.035) and visit age ≥40 years (OR ¼ 5.2; 95% CI: 1.4-18.9; P ¼ 0.012). However, there was not a significant association between aPL titers ≥40 and abnormalities in any valve (OR ¼ 2.6; 95% CI: 0.8-8.1; P ¼ 0.098). Regression models for the tricuspid valve showed no correlation in aPL titers ≥20 (OR ¼ 3.1; 95% CI: 0.9-9.9; P ¼ 0.062) and titers ≥40 (OR ¼ 2.3; 95% CI: 0.8-7.0; P ¼ 0.133), even though there was a trend toward significance. Regression models for the mitral valve showed no correlation in aPL titers ≥20 (OR ¼ 2.1; 95% CI: 0.7-6.5; P ¼ 0.195) and titers ≥40 (OR ¼ 1.5; 95% CI: 0.5-4.6; P ¼ 0.460), but were significant for disease duration (OR ¼ 3.2; 95% CI: 1.1-9.4; P ¼ 0.038). There was no significant association between abnormalities in any cardiac valve, tricuspid and mitral valve in regard to race, sex, age at diagnosis or platelet levels.
Multivariate logistic regression models, adjusted for both disease duration and age, showed a significant association between aPL titers ≥20 and an abnormality in any valve (OR ¼ 3.1; 95% CI: 1.0-8.9; P ¼ 0.041) and tricuspid valve (OR ¼ 3.3; 95% CI: 1.0-11.1; P ¼ 0.052). There was no association in multivariable regression models of the mitral valve (OR ¼ 2.1; 95% CI: 0.7-6.5; P ¼ 0.195). All regression models are shown in Table 2 .
Medication use history among the patients in our study reflected common medications used for the treatment of SLE, but were not significantly different based on aPl status. Patients with aPl levels ≥20 were more commonly taking hydroxychloroquine (93.3%versus 84.6%), azathioprine (46.7% versus 16.7%), rituximab (30.8% versus 8.3%), cyclophosphamide (28.6% versus 16.7%) and were less commonly taking mycophenolate (46.75% versus 61.5%). However, none of these differences in medication use were statistically significant, albeit limited by small sample size (only 30 of the 70 patients had complete medication use records).
DISCUSSION
Among this population of patients with SLE, 61% were found to have HVD by echocardiogram. Higher levels of aPLs were associated with an increased presence of HVD. Consistent with previous literature, patients who had aPL levels ≥20 units/mL also had a higher prevalence of HVD. Also, as expected, age of the patient at their study visit was a significant predictor of the presence of HVD. Importantly, the association between aPL level and HVD remained significant even when controlling for patient age. An association was also seen between SLE disease duration and mitral valve abnormalities. These findings suggest that aPLs are risk factors in the development of HVD among patients with SLE. Therefore, we suggest these "at risk" patients be screened via echocardiogram for HVD to reduce potential complications.
Although it has been reported that approximately 30-38% of patients with SLE will have cardiac vegetations, most of which are asymptomatic but still put them at risk of endocarditis, we did not find evidence of these in our study population. 10 Libman-Sacks Endocarditis (16 studies) of the total 23 studies assessed. Additionally, the mitral valve was found to be the most common site of abnormalities (19 studies). The second was the aortic valve (17 studies) and the third was the tricuspid (10 studies). Our cohort showed the mitral valve being most commonly affected, but the tricuspid valve being the second most commonly affected.
Our analysis showed only a significant association between aPL titers and HVD, not Libman-Sacks endocarditis. Our cohort showed regurgitation, 52 total cases, to be the most common valve abnormality affecting the mitral (18 cases) and tricuspid (19 cases) valves most commonly. Interestingly, our cohort showed only 2 cases of valve thickening and 2 cases of valve stenosis. Despite known association between high aPL titers and Libman-Sacks Endocarditis from the literature, we found no cases in our cohort. Reasons for fewer cases may be due to increased adherence to quality of care guidelines recommending hydroxychloroquine and aspirin for patients with APS. ). This study shed some light on the differences in cardiovascular manifestations between primary or secondary APS and aPL subtypes. In addition, this study found a strong correlation between aPL and Libman-Sacks endocarditis, an interesting contrast to our cohort. In addition, a 2011 study by Plazak et al 14 showed that IgG aPLs correlated with perfusion defects in the myocardium and increased right ventricular systolic pressure. However, it also showed that valvular and pericardial thickening was more likely related to laboratory markers of acute inflammation. Another systemic review by Mattos et al 15 consisting of a total of 1,593 SLE patient studies showed a significant association between aPL and HVD as well as Libman-Sacks endocarditis among 13 and 9 of the 20 studies assessed, respectively. Furthermore, a 2016 study by Mohammed et al 16 also showed correlation between aCL antibodies, LA, and anti-β 2 glycoprotein antibodies and mitral valve regurgitation (P ¼ 0.044, 0.006 and 0.023). These findings support our aPLs and HVD claim, yet also show contrast to our Libman-Sacks endocarditis findings.
It is important to emphasize that our study not only showed a statistically significant association between aPLs and HVD among patients with SLE but also provided the groundwork for other prospective studies to gauge the clinical significance of these valvular lesions. For example, a prospective cohort study by Perez-Villa et al, 17 consisting of 61 SLE patients matched with 40 controls, found that valvular lesion prevalence increased from 39-73% during the 10-year follow-up. Seven patients (12%) developed severe regurgitation, which was significantly related to aCL IgG antibodies (P ¼ 0.001). The combined incidence of stroke, peripheral embolism, need for valve surgery and death was 86% in patients with severe valvular regurgitation, compared with 25% in those without (P ¼ 0.003). Of particular importance is that 5 out of these 7 patients required valve replacement surgery with a mechanical valve, which in turn further increased the risk of thromboembolic events. Interestingly, our study had 4 patients that also underwent valve replacement surgery. Three of those cases had severe regurgitation thought to be due to SLE, and the fourth case was due to rheumatic heart disease. A 2015 paper studied the combined risk of thrombosis in patients with artificial valves and aCL antibodies concluding that inappropriate anticoagulation played a major role in thrombotic complications, while aCL IgM and IgG only played a minor role. 18 Another study showed that patients with HVD such as regurgitation, thickening, vegetations and LA had 2-3 times increased risk of cerebrovascular accidents (all P o 0.04). 19 There is compelling evidence to suggest that aPL-mediated HVD leads to significant clinical complications.
Our study had limitations, including those due to the cross-sectional study design limiting our ability to look at duration of aPL positivity before development of HVD. We also were limited by the type of imaging available. It has been well documented that transesophageal echocardiogram produce higher-resolution images of valves and is the superior technique for assessing valvular damage. 20, 21 Most of our patients underwent transthoracic echocardiograms; therefore, it is possible that the more frequent use of transthoracic echocardiography in our study may have resulted in missed cases of HVD.
Although we looked at aPL positivity in general, rather than the role each specific subtype, literature review suggests that the most predictive HVD risk factors include both the LA and the aCL IgG, having a pooled OR of 5.88 and 5.63, respectively. 12 Literature of HVD and anti-B2GPI antibodies specifically is limited. An interesting point is that the patients with SLE are at a 6-fold increased risk of venous thromboembolism with high titers of LA compared to only a 2-fold increased risk with high titers of aCL when compared to their negative aPL counterparts. 22 In conclusion, the prevailing pathophysiologic theory is that the aPL immune complexes deposit on valvular surfaces resulting in direct valvular damage via a thrombotic or inflammatory mechanism or both and can predispose patients to clinically significant valve disease and thromboembolic events. Our findings in a cohort of patients with SLE support those mechanisms, finding that the high levels of aPL antibodies, especially ≥40 units/mL, are significantly associated with HVD. Future directions should include completing prospective cohort studies to assess the clinical effect of valvular lesions. Such information can then better inform our HVD risk factor prediction and our screening recommendations in the care of patients with SLE.
SIGNIFICANCE AND INNOVATIONS
(1) This study explored whether high titers of aPLs are risk biomarkers for cardiac valve disease among patients with SLE.
(2) Cardiac valve disease mediated by aPL in patients with SLE most commonly presents as mitral and tricuspid regurgitation. (3) Libman-Sacks endocarditis was not associated with aPLs in this study population. (4) Although current evidence suggests that aPL-mediated valve disease predisposes to significant complications, additional prospective cohort studies are needed to characterize the clinical relevance of aPLmediated valvular damage.
